The transition phase of bridging preclinical to clinical vaccine development determines whether promising lab discoveries translate into viable human candidates. It requires extensive immunogenicity and toxicity testing in animal models, followed by the careful design of early-phase human trials. Regulatory compliance, scalability of manufacturing, and formulation adjustments must be addressed before clinical translation. Bridging preclinical to clinical vaccine development also involves selecting relevant biomarkers, determining appropriate dosing regimens, and mitigating risks. With the emergence of new platforms such as viral vectors and nucleic acid vaccines, this bridging phase has gained even more significance. Streamlined coordination between research institutions, industry, and regulatory authorities is key to accelerating the journey from bench to bedside.
Submit your abstract Today
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology Analysis of MPXV and VACV Peptides Underscores the Need to Consider Both MPXV Clades for Vaccine Development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Awareness and acceptability of rotavirus vaccine among mothers of under-five children in Gusau and Bungudu communities of Zamfara state, northwestern Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil